Who can take part?

You or someone you care for may be able to take part if you/they:

- are 18 years of age or older
- have been diagnosed with bullous pemphigoid
- have symptoms such as itching and blisters.

What else do I need to consider?

- The study team will explain the possible benefits and risks of the study.
- You do not have to take part in the study if you don't want to.
- If you choose to take part in the study, you can stop participating at any time.
- You will not be paid to take part in this study, but you may be reimbursed for reasonable travel costs during your participation.
- The investigational study medications and study-related tests will be provided to you at no cost.
- A team of doctors and nurses will monitor your health carefully during the study.



How do I get more information?

To find out more, contact the study team using the information provided here. Study participation is voluntary. By contacting us, you are under no obligation to take part in the study.

Patient Brochure, 29 Mar 2021 [V02 Global(en)]

FJORD

Patient Information

This brochure contains information about the FJORD Study for people with bullous pemphigoid. Bullous pemphigoid is a rare skin condition that can cause itching and large, painful, fluid-filled blisters.

This information should help you decide whether you or someone you know may want to take part in the study.

What is a clinical research study?

A clinical research study is a medical study that helps to answer important questions about an investigational medication, such as:

- Does it work?
- What amount, or dose, may work best?
- How safe is it?
- Are there side effects?

All medications must be tested in clinical research studies before they can be approved to prescribe to patients. Without people taking part in these studies, we would have no new medications.

Deciding to take part in a clinical research study is your decision. If you have any questions, you can contact the study team using the information provided in this brochure.

About the FJORD Study

The FJORD Study is being done to learn more about whether the study drug works to help improve bullous pemphigoid.

Why is the FJORD Study important?

The study is being done because treatment options for bullous pemphigoid are limited.

The study drug has been approved in more than 50 countries for treating severe asthma. It will now be studied to see if it improves the symptoms of bullous pemphigoid.

What will the FJORD Study involve?

If you take part, you will be in the FJORD Study for at least 10 months. You will need to:

- attend study center visits every 4 weeks to receive an injection of study drug or placebo (an injection without the active ingredient)
- complete a daily diary of your symptoms.

The study is made up of 4 periods.

Screening period (about 4 days)

You will visit the study center to see if the study is suitable for you and whether you want to take part.

Study treatment period (36 weeks)

You will visit the study center about 12 times for study assessments. You will receive the study medication (study drug or placebo) once every 4 weeks. Participants will also receive corticosteroids that they will take by mouth.

Extension treatment period

After completing the treatment period, participants may choose to join the extension treatment period. Everyone in this period will receive the study drug every 4 weeks for at least 1 year. You can decide at any time if you no longer want to receive the study drug.

Follow-up period (about 12 weeks after the last dose of study medication)

You will visit the study center once for study assessments after you have received the last dose of study medication.

In case of study disruption, if you cannot visit the study center, you may have a healthcare professional visit you at home, or a telemedicine visit by phone or video.